Released Mar 13, 2020, after the close
10-K filed Mar 16, 2020, 76 days after period end · 0001564590-20-010890
Q4 2019 · 10-K
Revenue$11.31M$11.31M −40.8% vs Q4 2018−7.9% vs Q3 2019
Net Income-$14.79M-$14.79M N/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.65-$0.65 N/M vs Q4 2018N/M vs Q3 2019
Operating Incomederived-$14,782,000N/M
Operating Cash Flowderived-$13,156,000N/M
Margins · derived
Operating margin-130.8%−113.6 pt vs Q4 2018
Net margin-130.8%−123.0 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|
| Revenue | $11.31M | $19.09M | $4.04M |
| Net Income | -$14.79M | -$1.49M | -$15.34M |
| EPS Diluted | -$0.65 | -$0.07 | -$33.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR